Bozhi Anjian

Bozhi Anjian (Hebei) Pharmaceutical Co., Ltd. is a private Chinese pharmaceutical company founded in 2021 and based in Shijiazhuang, Hebei Province. The company specializes in the development, contract manufacturing, and commercialization of chemical drug formulations, operating as a Marketing Authorization Holder (MAH). Bozhi Anjian's pipeline primarily focuses on small molecule generic drugs across multiple therapeutic areas, including anti-infectives and central nervous system disorders. Notable programs include faropenem sodium granules for children and peramivir injection, both of which have been submitted for marketing approval (NDA) in China, as well as betahistine mesilate tablets currently undergoing bioequivalence studies.